Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis

Liver International

Volumn 36, Issue 9, 2016, Pages 1239-1251

  Raffetti, Elena ^a   Fattovich, Giovanna ^b   Donato, Francesco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

hepatitis B; hepatocellular carcinoma; liver; meta analysis

Indexed keywords

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER RISK; CHRONIC HEPATITIS B; COCHRANE LIBRARY; EMBASE; HEPATITIS B VIRUS GENOTYPE C; HUMAN; INFORMATION RETRIEVAL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; BLOOD; COMPLICATION; DRINKING BEHAVIOR; EUROPE; FAR EAST; GENETICS; HEPATITIS B VIRUS; INCIDENCE; LIVER TUMOR; META ANALYSIS; NORTH AMERICA; RISK FACTOR; VIROLOGY;

VIRUS DNA;

ALCOHOL DRINKING; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; EUROPE; FAR EAST; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; NORTH AMERICA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84971298293     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13142     Document Type: Review

References (83)

1. Chen DS. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 2011; 54: 381–92.
2. Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7: 1742–54.
3. Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2015; 64: 1289–95.
4. Buti M, Fung S, Gane E, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015; 9: 243–50.
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–52.
6. Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses. PLoS One 2014; 9: e107177.
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1–34.
8. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12.
9. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–4.
10. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–9.
11. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289–93.
12. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507–39.
13. Gaiani S, Gramantieri L, Venturoli N, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979–85.
14. Yu MW, You SL, Chang AS, et al. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51: 5621–5.
15. Bedogni G, Miglioli L, Masutti F, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos study. Am J Gastroenterol 2008; 103: 2248–53.
16. Davidsdottir L, Duberg AS, Torner A, et al. Hepatocellular carcinoma in individuals with HBV infection or HBVHCV co-infection in a low endemic country. Scand J Gastroenterol 2010; 45: 944–52.
17. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol 2005; 77: 173–9.
18. Borresen ML, Koch A, Biggar RJ, et al. Hepatocellular carcinoma and other liver disease among Greenlanders chronically infected with hepatitis B virus: a population-based study. J Natl Cancer Institute 2011; 103: 1676–85.
19. Gordon SC, Lamerato LE, Rupp LB, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014; 12: 885–93.
20. Lim TH, Gane E, Moyes C, Borman B, Cunningham C. Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study. Gut 2015; 64: 966–72.
21. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432–8.
22. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 1000–5.
23. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–56.
24. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111–21.
25. Fang ZL, Sabin CA, Dong BQ, et al. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol 2008; 103: 2254–62.
26. Fwu CW, Chien YC, Kirk GD, et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Institute 2009; 101: 1019–27.
27. Kusakabe A, Tanaka Y, Inoue M, et al. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol 2011; 46: 117–24.
28. Lee M-H, Yang H-I, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013; 58: 546–54.
29. Loomba R, Liu J, Yang H-I, et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013; 11: 1636–45.
30. Muñoz A, Chen JG, Egner PA, et al. Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. Carcinogenesis 2011; 32: 860–5.
31. Oh J-K, Shin H-R, Lim MK, et al. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer 2012; 12: 452.
32. Sung F-Y, Jung C-M, Wu C-F, et al. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009; 137: 1687–97.
33. Wang C-S, Yao W-J, Chang T-T, Wang S-T, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009; 18: 2054–60.
34. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039–47.
35. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191–4.
36. Farzi H, Ebrahimi Daryani N, Mehrnoush L, Salimi S, Alavian SM. Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection. Hepatitis Monthly 2014; 14: e17537.
37. Tong MJ, Trieu J. Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis 2013; 14: 311–7.
38. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747–54.
39. Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 2014; 63: 1943–50.
40. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522–7.
41. Nakazawa T, Shibuya A, Takeuchi A, et al. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels. J Viral Hepat 2011; 18: e191–9.
42. Tai D-I, Lin S-M, Sheen I-S, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009; 49: 1859–67.
43. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–70.
44. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257–64.
45. Ieluzzi D, Covolo L, Donato F, Fattovich G. Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy. Dig Liver Dis 2014; 46: 427–32.
46. Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94: 2246–50.
47. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–7.
48. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121–9.
49. Tong MJ, Blatt LM, Kao J-H, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 6620–6.
50. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435–44.
51. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829–34.
52. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930–8.
53. Koo JS, Kim H, Park BK, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol 2008; 42: 738–43.
54. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263–7.
55. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971–5.
56. Lin S-M, Yu M-L, Lee C-M, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45–52.
57. Park BK, Park YN, Ahn SH, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007; 22: 383–8.
58. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650–5.
59. Tseng T-C, Liu C-J, Yang H-C, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140–9.e3.
60. Wong GL-H, Chan HL-Y, Mak CW-H, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537–47.
61. Xu B, Hu DC, Rosenberg DM et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003; 18: 1345–52.
62. Yang SC, Lu SN, Lee CM, et al. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatol Int 2013; 7: 489–99.
63. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12: 1295–303.
64. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192–9.
65. Yuen MF, Yuan HJ, Wong D, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610–4.
66. Benvegnù L, Chemello L, Noventa F, et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83: 901–9.
67. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132–7.
68. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: as cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886–95.
69. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141–7.
70. Tong MJ, Hsien C, Song JJ, et al. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci 2009; 54: 1337–46.
71. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007; 1: 267–73.
72. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82: 827–35.
73. Ishikawa T, Ichida T, Yamagiwa S, et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16: 1274–81.
74. Kato Y, Nakata K, Omagari K, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994; 74: 2234–8.
75. Kobayashi M, Ikeda K, Hosaka T, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78: 459–65.
76. Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–31.
77. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235–41.
78. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31(Suppl.): S137–42.
79. Sato A, Kato Y, Nakata K, Nakao K, et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis. J Gastroenterol Hepatol 1996; 11: 944–8.
80. Su TH, Hu TH, Lin CC, et al. Reduction of hepatocellular carcinoma in hepatitis B related cirrhosis patients with long-term entecavir therapy - An interim report of C-TEAM study. Hepatology 2013; 58: p301A.
81. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399–420.
82. Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int 2014; 34(Suppl. 1): 139–45.
83. Papatheodoridis GV, Chan HL-Y, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956–67.